Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients (Q37961577)

26 August 2017

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients (English)

1 reference

26 August 2017

0 references

3

1 reference

26 August 2017

Veronica Huber

2

0 references

author name string

Paola Filipazzi

series ordinal

1

1 reference

PubMed ID

22120756

26 August 2017

language of work or name

1 reference

27 November 2011

1 reference

Cancer Immunology, Immunotherapy

26 August 2017

1 reference

26 August 2017

61

1 reference

26 August 2017

2

1 reference

26 August 2017

255-263

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1161-9

26 August 2017

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

The role of myeloid cells in the promotion of tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Melanoma immunology: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Membrane vesicles as conveyors of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1161-9

10.1007/S00262-011-1161-9

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22120756